3-(4-nitrophenoxy)benzoyl chloride | 41370-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-nitrophenoxy)benzoyl chloride
• CAS: 41370-84-7
• 化学式: C₁₃H₈ClNO₄
• 分子量: 277.664
• InChiKey: DYZRGHYOMPRTPB-UHFFFAOYSA-N

物化性质

• 沸点：
  393.4±22.0 °C(Predicted)
• 密度：
  1.400±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-nitrophenoxy)benzoyl chloride 在 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 3-(4-aminophenoxy)-N,N-dimethylbenzamide
  参考文献：
  名称：

  Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors

  摘要：

  Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fit" protocol to improve the homology models of 5-HT2A receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT2A models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, K-i = 1959, 56, and 417 nM against 5-HT2A, 5-HT2B, and 5-HT2C, respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-target" 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

  DOI：

  10.1021/jm300338m
• 作为产物：
  描述：

  3-羟基苯甲酸乙酯 在 氯化亚砜 、 lithium hydroxide monohydrate 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 3-(4-nitrophenoxy)benzoyl chloride
  参考文献：
  名称：

  Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors

  摘要：

  Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fit" protocol to improve the homology models of 5-HT2A receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT2A models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, K-i = 1959, 56, and 417 nM against 5-HT2A, 5-HT2B, and 5-HT2C, respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-target" 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

  DOI：

  10.1021/jm300338m

文献信息

• Preparation and characterization of thermo-processable poly(benzimidazole imide)s with soluble and high heat-resistance containing N-phenyl-benzimidazole
  作者：Feng Guo、Ke Xu、Zhao Ke、Hao Zhang、Guangtao Qian、Hui Li、Dandan Li

  DOI：10.1016/j.polymer.2024.127017

  日期：2024.5

  synthetic strategy for N-phenyl substituted benzimidazole-derived diamines, including 2-(4-(4-aminophenoxy) phenyl)-1-phenyl-1H-benzo[d]imidazole-5-amine (para-diamine) and 2-(3-(4-aminophenoxy) phenyl)-1-phenyl-1H-benzo[d]imidazole-5-amine (meta-diamine). Two distinct series of N-phenyl substituted poly (benzimidazole imide)s (PBIPIs) were synthesized via reaction with different aromatic dianhydrides

  在本文中，我们提出了N-苯基取代的苯并咪唑衍生二胺的合成策略，包括2-(4-(4-氨基苯氧基)苯基)-1-苯基-1H-苯并[d]咪唑-5-胺(对-二胺）和2-（3-（4-氨基苯氧基）苯基）-1-苯基-1H-苯并[d]咪唑-5-胺（间二胺）。通过与不同的芳香族二酐反应合成了两个不同系列的N-苯基取代的聚苯并咪唑酰亚胺（PBIPIs）。模拟揭示了两种二胺单体的不同胺反应活性。所获得的 PBIPI 由于 N-苯基取代的苯并咪唑 (BI) 而表现出优异的耐热性。 N环境下失重5%（T）的温度范围为491-595°C，玻璃化转变温度为237-329°C。由于柔性醚连接基团的非共面性和庞大的苯侧基，PBIPI 表现出特定的溶解度特征。 PBIPI 的拉伸强度在 108 至 142 MPa 之间，拉伸模量为 4.0–5.9 GPa，断裂伸长率为 4.2–26.4%，表现出优异的机械性能。此外，由掺有 2
• Expression of human hepatitis C virus core antigen in tobacco plants by tobacco mosaic virus-based vector system
  作者：Aidong Han、Yule Liu、Li Xiao、Liangyi Kang、Yuman Zhang、Dongtian Li、Bo Tian

  DOI：10.1007/bf02884901

  日期：2000.3

  Tobacco mosaic virus (TMV) has the potential to highly express foreign gene. A novel TMV-based in trans expression system was constructed. A TMV mutant TSHc had its coat protein replaced with hepatitis C virus (HCV) core antigen gene. Another TMV mutant TSBD was replicase-detective. Coinfection of the two mutants could cause systemic infection in tobacco plants by in trans complementation of their functions. TSHc could effectively replicate and assemble to viral particles, which were a little longer than that of wild-type TMV. HCV core antigen was expressed in whole tobacco plants. A similar expression lever of HCV core antigen was detected on serial passages, which suggested that this viral expression system be stable.
• JOSIKAVA, YUKIXIRO;YAMAGUTI, KADZABURO;SUGIMOTO, KEHNITI;TANABEH, JOSIMIT+
  作者：JOSIKAVA, YUKIXIRO、YAMAGUTI, KADZABURO、SUGIMOTO, KEHNITI、TANABEH, JOSIMIT+

  DOI：——

  日期：——
• US3946090A
  申请人：——

  公开号：US3946090A

  公开（公告）日：1976-03-23
• US4061691A
  申请人：——

  公开号：US4061691A

  公开（公告）日：1977-12-06